Home Stock

Stock Research: BRAIN Biotech

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

BRAIN Biotech

GER:BNN DE0005203947
22
  • Value
    67
  • Growth
    15
  • Safety
    Safety
    3
  • Combined
    12
  • Sentiment
    59
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

BRAIN Biotech AG is a Germany-based company that supplies bio-based products and solutions for industrial processes. It operates in the nutrition, health, and environment industries. In the last fiscal year, the company had a market cap of $49 million, profits of $35 million, and revenue of $62 million with 325 employees.

more

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock BRAIN Biotech are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for BRAIN Biotech. The consolidated Value Rank has an attractive rank of 67, which means that the share price of BRAIN Biotech is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 67% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 59, which means that professional investors are more optimistic about the stock than for 59% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 15, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 3, meaning the company has a riskier financing structure than 97 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Analyst Opinions
Country Germany
Industry Specialty Chemicals
Size Small
Website brain-biotech.com
Index
CDAX
BRAIN Biotech stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
67 12 29 21
Growth
15 55 53 33
Safety
Safety
3 9 16 10
Sentiment
59 46 54 31
360° View
360° View
22 7 12 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 89 85 70
Opinions Change
50 68 50 50
Pro Holdings
n/a 17 10 21
Market Pulse
45 33 54 26
Sentiment
59 46 54 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
67 12 29 21
Growth
15 55 53 33
Safety Safety
3 9 16 10
Combined
12 1 8 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
51 73 64 39
Price vs. Earnings (P/E)
93 3 26 29
Price vs. Book (P/B)
100 20 25 17
Dividend Yield
1 1 1 1
Value
67 12 29 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
79 80 72 72
Profit Growth
6 89 26 53
Capital Growth
1 35 92 6
Stock Returns
56 20 21 45
Growth
15 55 53 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
1 3 64 56
Refinancing
29 70 35 23
Liquidity
5 12 6 10
Safety Safety
3 9 16 10

Similar Stocks

Discover high‑ranked alternatives to BRAIN Biotech and broaden your portfolio horizons.

Fresenius

GER:FRE
Country: Germany
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Henkel

GER:HEN3
Country: Germany
Industry: Household Products
Size: X-Large
Full Stock Analysis

Deutsche Telekom

GER:DTE
Country: Germany
Industry: Integrated Telecommunication
Size: XX-Large
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews